The global cell culture market size was valued at USD 21.05 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 11.9% from 2022 to 2030. Advancements in 3D culture technologies and their increasing adoption for biopharmaceutical production, drug discovery, and tissue engineering applications are anticipated to boost the industry's growth. Recent developments in gene expression technologies have enabled the production of novel vaccines and biopharmaceuticals, thereby increasing the research & development applications of cell culture techniques. Moreover, a rise in the number of cancer research projects and broadening scope of applications for gene therapies are expected to drive the market.
The COVID-19 pandemic has boosted the demand for cell culture products due to the significant role played by cell culture technologies in the discovery of novel diagnostic and therapeutic options for the disease. For instance, research applications of cell lines such as high-throughput COVID-19 drug screening for identification of potential drug candidates and investigations aimed at understanding the mechanism of viral entry into the host cells are expected to positively affect the market growth. Furthermore, culturing techniques offer essential tools for the production of viral particles for vaccine development, thereby broadening the growth prospects in this domain.
Demand for cytological offerings provided by contract research organizations is expected to rise due to the cost-intensiveness and expertise required for setting up cell culture infrastructure. Moreover, regenerative therapy research has attained tremendous growth in recent years due to the large amounts of investments funneled into this domain. As cell culture techniques constitute an essential step in such research applications, the market is expected to witness significant growth in the near future.
Key players involved in the market are undertaking initiatives to extend their product portfolios and strengthen their market position. For instance, in January 2022, Cytiva (Danaher Corporation) collaborated with Nucleus Biologics for the development of custom culture media for cell and gene therapies. Furthermore, expansion of the existing service offerings is being undertaken by emerging players to enhance their market presence. For instance, in February 2022, KromaTiD expanded its service offerings with the launch of cell and blood culture isolation, processing, and quality control services.
In addition, continuous advancements in regenerative medicines and high unmet medical needs in emerging markets are expected to drive the adoption of cell culture technologies. Government initiatives in this domain are further contributing to industry growth. For instance, in January 2022, India’s Union Health Ministry amended the New Drugs & Clinical Trials Rules for the addition of cell-derived or stem cell-derived products into the scope of new drugs. This provided a robust regulatory structure for governing the production of cell-derived products in the country and is expected to positively affect the industry growth.
Furthermore, growth in the prevalence of chronic diseases, such as cancer and cardiovascular diseases, has led to an increased focus on cytological studies, leading to rising demand for culture systems and media products. For instance, according to the WHO, cardiovascular diseases lead to over 17.9 million deaths each year. Such a high number of fatalities is anticipated to attract further research attention in this domain and increase the growth opportunities for cell culture offerings.
Media held the largest revenue share of over 50.0% in 2021 due to the high demand for media products for research and development applications. The availability of a variety of serum- and animal-component-free and customized media alternatives has increased the market penetration for media products. Furthermore, specialized media for stem cell applications is being increasingly commercialized, which is expected to boost the growth of the segment. For instance, companies such as Thermo Fisher Scientific, Inc. and Sartorius AG offer media products optimized for stem cell culture.
The reagents segment is expected to register the fastest CAGR over the forecast period due to the increasing significance of albumin for carrying serum-derived substances that support mammalian cultures. Other reagents such as antibiotics and amino acids are being increasingly used for applications in primary cultures to ensure the maintenance of a sterile and nutrient-rich environment in the culture systems. These factors are expected to significantly boost the segment growth.
Culture systems dominated the market and accounted for over 25.0% share in 2021. The segment is also expected to register the fastest CAGR over the forecast period due to the development of technologically advanced and automated culturing systems. For instance, in March 2022, CELLINK launched its BIO CELLX bio-dispensing platform for the automation of 3D cell-based assays for drug discovery and cancer research. Such product launches are likely to broaden the growth prospects for the segment.
Centrifuges are anticipated to witness significant growth over the forecast period as benchtop centrifuges are gaining efficiency in operations and they offer reliability for everyday laboratory use. Furthermore, bioprocessing centrifuges are commercially available for high-quality, rapid, and high-yield cell separation, which can increase the adoption of the technique. With the growing need for centrifuges for the production of gene therapies, antibodies, and vaccines, the demand for the product is expected to grow in the near future.
The biopharmaceuticals segment held the largest revenue share of over 25.0% in 2021. Due to the involvement of mammalian cell lines, such as the Chinese hamster ovary, in the manufacturing of biopharmaceuticals and the rising demand for non-conventional drugs, biopharmaceutical applications of cell culture techniques are expected to witness growth. In addition, the development of several grafting techniques and personalized treatment options in recent years has expanded the growth prospects in the biopharmaceutical domain.
Vaccine production is projected to expand at a lucrative CAGR over the forecast period due to the increasing importance of culturing techniques for the production of viral vaccines grown using Madin-Darby Canine Kidney, pMK, Vero, or human lines such as HEK 293 and MRC 5. With accelerated vaccine approval processes and large investments in vaccine manufacturing fueled by the COVID-19 pandemic, vaccine production applications of the technique are likely to positively affect the industry growth.
North America held the largest revenue share of over 40.0% in 2021 due to high research and development investments, the presence of a well-established scientific infrastructure, significant demand for animal component-free media, and other factors.
Furthermore, ongoing research and expansion of the biopharmaceutical sector in the U.S. are expected to boost industry growth in the region. The presence of key players such as Bio-Rad Laboratories, Inc.; Thermo Fisher Scientific, Inc.; and Becton, Dickinson, and Company can significantly drive the market.
The Asia Pacific region is projected to expand at the fastest CAGR over the forecast period due to the growing healthcare expenditure, rising awareness regarding cell and gene therapies, and a large potential for clinical research applications. Furthermore, the rapid adoption of scientific technologies and emerging therapeutics, such as regenerative medicines and cancer immunotherapies, is likely to strengthen the industry's growth in the near future.
Key market players are undertaking strategic initiatives such as mergers and acquisitions, expansions, and new product development to extend their product portfolio and strengthen their market presence. For instance, in January 2022, BioIVT launched its GMP Grade Human AB Serum specialized for gene therapy manufacturing. Some prominent players in the global cell culture market include:
Bio-Rad Laboratories, Inc.
Thermo Fisher Scientific, Inc.
Becton, Dickinson and Company
Merck KGaA
Sartorius AG
VWR International, LLC
Eppendorf SE
PromoCell GmbH
Bio-Techne Corporation
BioSpherix, Ltd.
Report Attribute |
Details |
Market size value in 2022 |
USD 24.60 billion |
Revenue forecast in 2030 |
USD 60.27 billion |
Growth rate |
CAGR of 11.9% from 2022 to 2030 |
Base year for estimation |
2021 |
Historical data |
2018 - 2020 |
Forecast period |
2022 - 2030 |
Quantitative units |
Revenue in USD million/billion and CAGR from 2022 to 2030 |
Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
Segments covered |
Consumable, product, application, region |
Regional scope |
North America; Europe; Asia Pacific; Latin America; MEA |
Country scope |
U.S.; Canada; U.K.; Germany; France; Italy; Spain; Japan; China; India; Australia; South Korea; Brazil; Mexico; South Africa; Saudi Arabia; UAE |
Key companies profiled |
Bio-Rad Laboratories, Inc.; Thermo Fisher Scientific, Inc.; Becton, Dickinson and Company; Merck KGaA; Sartorius AG; VWR International, LLC; Eppendorf SE; PromoCell GmbH; Bio-Techne Corporation; BioSpherix, Ltd. |
Customization scope |
Free report customization (equivalent up to 8 analyst’s working days) with purchase. Addition or alteration to country, regional & segment scope. |
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2018 to 2030. For the purpose of this report, Grand View Research has segmented the global cell culture market report on the basis of consumables, product, application, and region:
Consumable Outlook (Revenue, USD Million, 2018 - 2030)
Media
Minimum Essential Media (MEM)
RPMI 1640 Media
DMEM/F-12 Media
F-10 Serum Free Media
BME Media
Insect Media
Other Media
Sera
Fetal Bovine Serum
Other AnimalSerum
Reagents
Albumin
Other
Product Outlook (Revenue, USD Million, 2018 - 2030)
Culture Systems
Incubators
Centrifuges
Cryostorage Equipment
Biosafety Equipment
Pipetting Instruments
Application Outlook (Revenue, USD Million, 2018 - 2030)
Biopharmaceuticals
Tissue Culture & Engineering
Vaccine Production
Drug Development
Gene Therapy
Toxicity Testing
Cancer Research
Others
Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Europe
U.K.
Germany
France
Italy
Spain
Asia Pacific
Japan
China
India
Australia
South Korea
Latin America
Brazil
Mexico
Middle East and Africa (MEA)
South Africa
Saudi Arabia
UAE
b. The global cell culture market size was estimated at USD 21.05 billion in 2021 and is expected to reach USD 24.60 billion in 2022.
b. The global cell culture market is expected to grow at a compound annual growth rate of 11.9% from 2022 to 2030 to reach USD 60.27 billion by 2030.
b. North America dominated the cell culture market with a share of 40.55% in 2021. This is attributed to a high extent of research and development investments, the presence of a well-established scientific infrastructure, significant demand for animal component-free media, and other factors.
b. Some key players operating in the cell culture market include Bio-Rad Laboratories, Inc.; Thermo Fisher Scientific, Inc.; Becton, Dickinson and Company; Merck KGaA; Sartorius AG; VWR International, LLC; Eppendorf SE; PromoCell GmbH; Bio-Techne Corporation; BioSpherix, Ltd.
b. Key factors that are driving the cell culture market growth include advancements in 3D cell culture technologies and their increasing adoption for biopharmaceutical production, drug discovery, and tissue engineering applications.
GET A FREE SAMPLE
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member
Leading SME award by D&B
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
"The quality of research they have done for us has been excellent."
Biopharmaceutical innovators are at the forefront of the human response to the coronavirus pandemic. A significant number of major biotech firms are in the midst of a race to investigate the Sars-Cov-2 genome and prepare a viable vaccine for the same. As compared to the speed of response to SARS/MERs etc, the biotech entities are investigating SARs-Cov-2 at an unprecedented rate and a considerable amount of funds are being put into the R&D. With multiple candidates in trial, the public and private sectors are anticipated to work in unison for the foreseeable period, until a vaccine is developed for Covid-19. The report will account for Covid19 as a key market contributor.
We value your investment and offer free customization with every report to fulfil your exact research needs.